{
    "clinical_study": {
        "@rank": "122612", 
        "arm_group": [
            {
                "arm_group_label": "Treatment Group 1", 
                "arm_group_type": "Experimental", 
                "description": "Patients will receive Albuterol SPIROMAX during Treatment Visit 1 and Placebo during Treatment Visit 2."
            }, 
            {
                "arm_group_label": "Treatment Group 2", 
                "arm_group_type": "Experimental", 
                "description": "Patients will receive Placebo during Treatment Visit 1 and Albuterol SPIROMAX during Treatment Visit 2."
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of this study is to evaluate the efficacy of a single dose (2\n      inhalations, 180 mcg total) of Albuterol SPIROMAX (90 mcg per inhalation) versus placebo in\n      patients with EIB."
        }, 
        "brief_title": "Efficacy of Albuterol SPIROMAX\u00ae in Adult and Adolescent Patients With Exercise-Induced Bronchoconstriction (EIB)", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "condition": "Exercise-Induced Bronchoconstriction (EIB)", 
        "detailed_description": {
            "textblock": "This study is a single-dose, randomized, double-blind, placebo-controlled, 2-treatment,\n      2-sequence, 2-way crossover, multicenter study in patients with a documented history of EIB,\n      with or without underlying asthma. Each patient will participate in the study for\n      approximately 5 weeks. Each patient will complete 2 screening visits (SV1 and SV2), 2\n      treatment visits (TV1 and TV2), and a follow-up telephone call (FV)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Informed consent/assent: For patients 18 to 50 years of age, inclusive, written\n             informed consent signed and dated by the patient before conducting any study related\n             procedures and review of Health Insurance Portability and Accountability Act of 1996\n             (HIPAA) authorization; for patients 12 to 17 years of age, inclusive, written\n             informed consent signed and dated by the parent/legal guardian and written assent\n             signed and dated by the patient before conducting any study related procedure and\n             review of HIPAA authorization.\n\n          -  Male or female patients 12 to 50 years of age, inclusive, as of SV1.\n\n          -  If female, is currently not pregnant, breastfeeding, or attempting to become\n             pregnant, has a negative serum pregnancy test, and is of non-childbearing potential.\n\n          -  Documented history of EIB, with or without underlying asthma. The underlying asthma\n             must be well-controlled (in the investigator's judgment) as per the National Asthma\n             Education and Prevention Program, Expert Panel Report (NAEPP, EPR-3).\n\n          -  Other criteria apply.\n\n        Exclusion Criteria:\n\n          -  Requires a rescue bronchodilator following the exercise challenge at SV1 for a\n             decrease in FEV1 that does not return to within 20% of their pre-exercise challenge\n             FEV1 within 30 minutes after administration of the rescue medication.\n\n          -  Pregnant, nursing, or plans to become pregnant or donate gametes (ova or sperm) for\n             in vitro fertilization during the study period or for 30 days after the patient's\n             last study related visit (for eligible patients only-if applicable).\n\n          -  Participation in any investigational drug trial within the 30 days preceding SV1 or\n             planned participation in another investigational drug trial at any time during this\n             trial.\n\n          -  A known hypersensitivity to albuterol or any of the excipients in the formulation.\n\n          -  History of severe milk protein allergy.\n\n          -  History of a respiratory infection or disorder (including, but not limited to\n             bronchitis, pneumonia, otitis media, acute or chronic sinusitis, influenza, etc) that\n             has not resolved within the 2 weeks preceding SV1.\n\n          -  Other criteria apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01791972", 
            "org_study_id": "ABS-AS-302"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Treatment Group 1", 
                    "Treatment Group 2"
                ], 
                "description": "Albuterol SPIROMAX 90 mcg/inhalation", 
                "intervention_name": "Albuterol SPIROMAX", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Treatment Group 1", 
                    "Treatment Group 2"
                ], 
                "description": "Placebo matching SPIROMAX", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Albuterol"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Exercise-Induced Bronchoconstriction (EIB)", 
            "Spiromax\u00ae", 
            "Albuterol sulfate"
        ], 
        "lastchanged_date": "May 23, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "Teva Investigational Site 10557"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Denver", 
                        "country": "United States", 
                        "state": "Colorado"
                    }, 
                    "name": "Teva Investigational Site 10555"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Denver", 
                        "country": "United States", 
                        "state": "Colorado"
                    }, 
                    "name": "Teva Investigational Site 10558"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wheaton", 
                        "country": "United States", 
                        "state": "Maryland"
                    }, 
                    "name": "Teva Investigational Site 10559"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "North Dartmouth", 
                        "country": "United States", 
                        "state": "Massachusetts"
                    }, 
                    "name": "Teva Investigational Site 10560"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Raleigh", 
                        "country": "United States", 
                        "state": "North Carolina"
                    }, 
                    "name": "Teva Investigational Site 10556"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Single-Dose Study to Assess the Efficacy of Albuterol SPIROMAX\u00ae in Adult and Adolescent Patients With Exercise-Induced Bronchoconstriction (EIB)", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The percentage fall is defined at all time points as 100*(baseline-post baseline)/baseline. The baseline FEV1 is the test day FEV1 measured 5 minutes before the exercise challenge (30 minutes postdose).", 
            "measure": "Maximum percentage fall from baseline in forced expiratory volume in 1 second (FEV1)", 
            "safety_issue": "No", 
            "time_frame": "up to 60 minutes post-exercise challenge"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01791972"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percentage of patients whose maximum percentage decrease from the baseline FEV1 post-exercise challenge is <10%", 
                "safety_issue": "No", 
                "time_frame": "up to 60 minutes post-exercise challenge"
            }, 
            {
                "measure": "Percentage of patients whose maximum percentage decrease from the baseline FEV1 post-exercise challenge is >20%", 
                "safety_issue": "No", 
                "time_frame": "up to 60 minutes post-exercise challenge"
            }, 
            {
                "description": "Safety will be monitored throughout the study by obtaining physical examinations, vital signs, ECGs, peak expiratory flow rates (PEFs), and the occurrence of adverse events.", 
                "measure": "Safety Parameters", 
                "safety_issue": "Yes", 
                "time_frame": "From signing of the informed consent to the end of study (approximately 5 weeks)"
            }
        ], 
        "source": "Teva Pharmaceutical Industries", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Teva Pharmaceutical Industries", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}